United States Biotechnology & Medical Research

Contineum Therapeutics, Inc. (CTNM)

Contineum Therapeutics experienced significant insider selling over the past quarter, totaling approximately $333,865. Key executives, including the CEO and Chief Scientific Officer, executed multiple planned divestments. These activities occurred alongside a 34.3% decline in share value and a recent earnings report reflecting an 8.9% miss on projected performance metrics.
Ticker: CTNM Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Daniel Lorrain Officer Officer
Transaction date
Proposed sale
Price
99.56
Quantity 79,929
Value US$1,323,069
Daniel Lorrain Officer Officer
Transaction date
Proposed sale
Price
324.79
Quantity 45,961
Value US$965,858
1.0
Stengone Carmine N. CEO and President Executive Director
Transaction date
Planned sale
Price
397.41
Quantity 95,446 +26.3%
Value US$4,391,543
1.0
CARMINE STENGONE Director; Officer Executive Director
Transaction date
Proposed sale
Price
16.70
Quantity 2,500
Value US$41,750
Daniel Lorrain Officer Officer
Transaction date
Proposed sale
Price
16.24
Quantity 9,520
Value US$154,605
1.0
Stengone Carmine N. CEO and President Executive Director
Transaction date
Planned sale
Price
16.01
Quantity 2,500 -12.7%
Value US$40,029
1.0
CARMINE STENGONE Director; Officer Executive Director
Transaction date
Proposed sale
Price
15.49
Quantity 2,500
Value US$38,725
Daniel Lorrain Officer Officer
Transaction date
Proposed sale
Price
15.49
Quantity 9,520
Value US$147,465
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
16.00
Quantity 25 -0.0%
Value US$400
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
16.00
Quantity 1,015 -0.7%
Value US$16,240
1.0
Stengone Carmine N. CEO and President Executive Director
Transaction date
Planned sale
Price
16.00
Quantity 2,500 -12.7%
Value US$40,000
1.0
CARMINE STENGONE Director; Officer Executive Director
Transaction date
Proposed sale
Price
14.56
Quantity 2,500
Value US$36,400
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
16.24
Quantity 2,501 -1.8%
Value US$40,608
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
15.67
Quantity 5,852 -4.1%
Value US$91,682
Daniel Lorrain Officer Officer
Transaction date
Proposed sale
Price
16.39
Quantity 9,520
Value US$156,033
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
16.04
Quantity 28,826 -17.1%
Value US$462,288
Watkins Tim CMO & Head of Development Officer
Transaction date
Planned sale
Price
16.02
Quantity 10,833 -54.7%
Value US$173,590
1.0
Stengone Carmine N. CEO and President Executive Director
Transaction date
Planned sale
Price
16.01
Quantity 10,000 -36.7%
Value US$160,080
Daniel Lorrain Officer Officer
Transaction date
Proposed sale
Price
15.00
Quantity 28,826
Value US$432,390
1.0
CARMINE STENGONE Director; Officer Executive Director
Transaction date
Proposed sale
Price
15.00
Quantity 10,000
Value US$150,000
TIMOTHY WATKINS Officer Officer
Transaction date
Proposed sale
Price
15.00
Quantity 10,833
Value US$162,495
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
13.16
Quantity 4,170 -2.9%
Value US$54,862
DANIEL LORRAIN Officer Officer
Transaction date
Proposed sale
Price
13.49
Quantity 4,170
Value US$56,253
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
13.84
Quantity 300 -0.2%
Value US$4,152
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
13.06
Quantity 3,870 -2.6%
Value US$50,542
DANIEL LORRAIN Officer Officer
Transaction date
Proposed sale
Price
12.82
Quantity 4,170
Value US$53,459
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
13.43
Quantity 4,170 -2.7%
Value US$56,014
DANIEL LORRAIN Officer Officer
Transaction date
Proposed sale
Price
13.44
Quantity 914
Value US$12,284
Watkins Tim CMO & Head of Development Officer
Transaction date
Planned sale
Price
15.02
Quantity 3,611 -100.0%
Value US$54,220
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
15.01
Quantity 4,170 -2.7%
Value US$62,585
1.0
Stengone Carmine N. CEO and President Executive Director
Transaction date
Planned sale
Price
16.02
Quantity 2,700 -15.3%
Value US$43,242
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
16.01
Quantity 3,824 -2.4%
Value US$61,228
1.0
Stengone Carmine N. CEO and President Executive Director
Transaction date
Planned sale
Price
16.02
Quantity 4,400 -22.7%
Value US$70,486
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
16.03
Quantity 4,300 -2.7%
Value US$68,936
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
16.00
Quantity 100 -0.1%
Value US$1,600
1.0
Stengone Carmine N. CEO and President Executive Director
Transaction date
Planned sale
Price
16.00
Quantity 400 -2.6%
Value US$6,400
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
16.00
Quantity 400 -0.3%
Value US$6,400
DANIEL LORRAIN Officer Officer
Transaction date
Proposed sale
Price
15.75
Quantity 16,050
Value US$252,788
1.0
CARMINE STENGONE Director; Officer Executive Director
Transaction date
Proposed sale
Price
15.75
Quantity 7,500
Value US$118,125
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
15.25
Quantity 1,170 -0.7%
Value US$17,837
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
14.82
Quantity 3,000 -1.9%
Value US$44,469
DANIEL LORRAIN Officer Officer
Transaction date
Proposed sale
Price
14.38
Quantity 4,170
Value US$59,965
Watkins Tim CMO & Head of Development Officer
Transaction date
Planned sale
Price
14.48
Quantity 811 -100.0%
Value US$11,747
Watkins Tim CMO & Head of Development Officer
Transaction date
Planned sale
Price
14.09
Quantity 2,800 -77.5%
Value US$39,441
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
11.13
Quantity 500 -0.3%
Value US$5,565
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
10.35
Quantity 3,670 -2.2%
Value US$37,978
DANIEL LORRAIN Officer Officer
Transaction date
Proposed sale
Price
11.39
Quantity 4,170
Value US$47,496
Watkins Tim CMO & Head of Development Officer
Transaction date
Planned sale
Price
12.06
Quantity 3,611 -100.0%
Value US$43,558
TIMOTHY WATKINS Officer Officer
Transaction date
Proposed sale
Price
12.41
Quantity 10,833
Value US$134,438
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
12.23
Quantity 4,170 -2.5%
Value US$51,009
DANIEL LORRAIN Officer Officer
Transaction date
Proposed sale
Price
12.26
Quantity 4,170
Value US$51,124
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
16.02
Quantity 1,010 -0.6%
Value US$16,177
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
17.05
Quantity 99 -0.1%
Value US$1,688
Lorrain Daniel S. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
16.37
Quantity 6,091 -3.5%
Value US$99,733
DANIEL LORRAIN Officer Officer
Transaction date
Proposed sale
Price
17.21
Quantity 26,370
Value US$453,828
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-11-04 2026-11-04 PrS Proposed sale
Daniel Lorrain

Officer

Officer
79,929
99.56
US$1,323,069 		79,929 99.56 US$1,323,069
2026-10-01 2026-10-01 PrS Proposed sale
Daniel Lorrain

Officer

Officer
45,961
324.79
US$965,858 		45,961 324.79 US$965,858
2026-09-08 2026-09-08 PlS Planned sale
1.0
Stengone Carmine N.

CEO and President

Executive Director
95,446 +26.3%
397.41
US$4,391,543 		95,446 +26.3% 397.41 US$4,391,543
2026-09-08 2026-09-08 PrS Proposed sale
1.0
CARMINE STENGONE

Director; Officer

Executive Director
2,500
16.70
US$41,750 		2,500 16.70 US$41,750
2026-09-01 2026-09-01 PrS Proposed sale
Daniel Lorrain

Officer

Officer
9,520
16.24
US$154,605 		9,520 16.24 US$154,605
2026-08-03 2026-08-03 PlS Planned sale
1.0
Stengone Carmine N.

CEO and President

Executive Director
2,500 -12.7%
16.01
US$40,029 		2,500 -12.7% 16.01 US$40,029
2026-08-03 2026-08-03 PrS Proposed sale
1.0
CARMINE STENGONE

Director; Officer

Executive Director
2,500
15.49
US$38,725 		2,500 15.49 US$38,725
2026-08-03 2026-08-03 PrS Proposed sale
Daniel Lorrain

Officer

Officer
9,520
15.49
US$147,465 		9,520 15.49 US$147,465
2026-07-10 2026-07-09 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
25 -0.0%
16.00
US$400 		25 -0.0% 16.00 US$400
2026-07-10 2026-07-08 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
1,015 -0.7%
16.00
US$16,240 		1,015 -0.7% 16.00 US$16,240
2026-07-08 2026-07-08 PlS Planned sale
1.0
Stengone Carmine N.

CEO and President

Executive Director
2,500 -12.7%
16.00
US$40,000 		2,500 -12.7% 16.00 US$40,000
2026-07-08 2026-07-08 PrS Proposed sale
1.0
CARMINE STENGONE

Director; Officer

Executive Director
2,500
14.56
US$36,400 		2,500 14.56 US$36,400
2026-07-02 2026-07-01 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
2,501 -1.8%
16.24
US$40,608 		2,501 -1.8% 16.24 US$40,608
2026-07-02 2026-07-01 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
5,852 -4.1%
15.67
US$91,682 		5,852 -4.1% 15.67 US$91,682
2026-07-01 2026-07-01 PrS Proposed sale
Daniel Lorrain

Officer

Officer
9,520
16.39
US$156,033 		9,520 16.39 US$156,033
2026-07-02 2026-06-30 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
28,826 -17.1%
16.04
US$462,288 		28,826 -17.1% 16.04 US$462,288
2026-07-01 2026-06-30 PlS Planned sale
Watkins Tim

CMO & Head of Development

Officer
10,833 -54.7%
16.02
US$173,590 		10,833 -54.7% 16.02 US$173,590
2026-07-01 2026-06-30 PlS Planned sale
1.0
Stengone Carmine N.

CEO and President

Executive Director
10,000 -36.7%
16.01
US$160,080 		10,000 -36.7% 16.01 US$160,080
2026-06-30 2026-06-30 PrS Proposed sale
Daniel Lorrain

Officer

Officer
28,826
15.00
US$432,390 		28,826 15.00 US$432,390
2026-06-30 2026-06-30 PrS Proposed sale
1.0
CARMINE STENGONE

Director; Officer

Executive Director
10,000
15.00
US$150,000 		10,000 15.00 US$150,000
2026-06-30 2026-06-30 PrS Proposed sale
TIMOTHY WATKINS

Officer

Officer
10,833
15.00
US$162,495 		10,833 15.00 US$162,495
2026-06-01 2026-06-01 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
4,170 -2.9%
13.16
US$54,862 		4,170 -2.9% 13.16 US$54,862
2026-06-01 2026-06-01 PrS Proposed sale
DANIEL LORRAIN

Officer

Officer
4,170
13.49
US$56,253 		4,170 13.49 US$56,253
2026-05-01 2026-05-01 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
300 -0.2%
13.84
US$4,152 		300 -0.2% 13.84 US$4,152
2026-05-01 2026-05-01 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
3,870 -2.6%
13.06
US$50,542 		3,870 -2.6% 13.06 US$50,542
2026-05-01 2026-05-01 PrS Proposed sale
DANIEL LORRAIN

Officer

Officer
4,170
12.82
US$53,459 		4,170 12.82 US$53,459
2026-04-06 2026-04-06 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
4,170 -2.7%
13.43
US$56,014 		4,170 -2.7% 13.43 US$56,014
2026-04-06 2026-04-06 PrS Proposed sale
DANIEL LORRAIN

Officer

Officer
914
13.44
US$12,284 		914 13.44 US$12,284
2026-03-02 2026-03-02 PlS Planned sale
Watkins Tim

CMO & Head of Development

Officer
3,611 -100.0%
15.02
US$54,220 		3,611 -100.0% 15.02 US$54,220
2026-03-02 2026-03-02 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
4,170 -2.7%
15.01
US$62,585 		4,170 -2.7% 15.01 US$62,585
2026-02-26 2026-02-25 PlS Planned sale
1.0
Stengone Carmine N.

CEO and President

Executive Director
2,700 -15.3%
16.02
US$43,242 		2,700 -15.3% 16.02 US$43,242
2026-02-26 2026-02-25 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
3,824 -2.4%
16.01
US$61,228 		3,824 -2.4% 16.01 US$61,228
2026-02-26 2026-02-24 PlS Planned sale
1.0
Stengone Carmine N.

CEO and President

Executive Director
4,400 -22.7%
16.02
US$70,486 		4,400 -22.7% 16.02 US$70,486
2026-02-26 2026-02-24 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
4,300 -2.7%
16.03
US$68,936 		4,300 -2.7% 16.03 US$68,936
2026-02-20 2026-02-19 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
100 -0.1%
16.00
US$1,600 		100 -0.1% 16.00 US$1,600
2026-02-13 2026-02-11 PlS Planned sale
1.0
Stengone Carmine N.

CEO and President

Executive Director
400 -2.6%
16.00
US$6,400 		400 -2.6% 16.00 US$6,400
2026-02-13 2026-02-11 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
400 -0.3%
16.00
US$6,400 		400 -0.3% 16.00 US$6,400
2026-02-11 2026-02-11 PrS Proposed sale
DANIEL LORRAIN

Officer

Officer
16,050
15.75
US$252,788 		16,050 15.75 US$252,788
2026-02-11 2026-02-11 PrS Proposed sale
1.0
CARMINE STENGONE

Director; Officer

Executive Director
7,500
15.75
US$118,125 		7,500 15.75 US$118,125
2026-02-05 2026-02-03 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
1,170 -0.7%
15.25
US$17,837 		1,170 -0.7% 15.25 US$17,837
2026-02-05 2026-02-03 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
3,000 -1.9%
14.82
US$44,469 		3,000 -1.9% 14.82 US$44,469
2026-02-03 2026-02-03 PrS Proposed sale
DANIEL LORRAIN

Officer

Officer
4,170
14.38
US$59,965 		4,170 14.38 US$59,965
2026-01-30 2026-01-28 PlS Planned sale
Watkins Tim

CMO & Head of Development

Officer
811 -100.0%
14.48
US$11,747 		811 -100.0% 14.48 US$11,747
2026-01-30 2026-01-28 PlS Planned sale
Watkins Tim

CMO & Head of Development

Officer
2,800 -77.5%
14.09
US$39,441 		2,800 -77.5% 14.09 US$39,441
2026-01-06 2026-01-05 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
500 -0.3%
11.13
US$5,565 		500 -0.3% 11.13 US$5,565
2026-01-06 2026-01-05 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
3,670 -2.2%
10.35
US$37,978 		3,670 -2.2% 10.35 US$37,978
2026-01-05 2026-01-05 PrS Proposed sale
DANIEL LORRAIN

Officer

Officer
4,170
11.39
US$47,496 		4,170 11.39 US$47,496
2025-12-30 2025-12-29 PlS Planned sale
Watkins Tim

CMO & Head of Development

Officer
3,611 -100.0%
12.06
US$43,558 		3,611 -100.0% 12.06 US$43,558
2025-12-29 2025-12-29 PrS Proposed sale
TIMOTHY WATKINS

Officer

Officer
10,833
12.41
US$134,438 		10,833 12.41 US$134,438
2025-12-30 2025-12-23 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
4,170 -2.5%
12.23
US$51,009 		4,170 -2.5% 12.23 US$51,009
2025-12-23 2025-12-23 PrS Proposed sale
DANIEL LORRAIN

Officer

Officer
4,170
12.26
US$51,124 		4,170 12.26 US$51,124
2024-11-27 2024-11-25 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
1,010 -0.6%
16.02
US$16,177 		1,010 -0.6% 16.02 US$16,177
2024-11-20 2024-11-18 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
99 -0.1%
17.05
US$1,688 		99 -0.1% 17.05 US$1,688
2024-11-20 2024-11-18 PlS Planned sale
Lorrain Daniel S.

Chief Scientific Officer

Officer
6,091 -3.5%
16.37
US$99,733 		6,091 -3.5% 16.37 US$99,733
2024-11-18 2024-11-18 PrS Proposed sale
DANIEL LORRAIN

Officer

Officer
26,370
17.21
US$453,828 		26,370 17.21 US$453,828
Explore more

More insider trading research around Contineum Therapeutics, Inc.

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America